Positive topline results from phase III APOLLO study of daratumumab plus pomalidomide and dexamethasone in the treatment of patients with RRMM

On July 31, 2020, positive results from the phase III APOLLO study (MMY3013; NCT03180736) were reported for daratumumab plus pomalidomide and dexamethasone (Pd) versus Pd alone in the treatment of patients with relapsed or refractory multiple myeloma, who have previously been treated with an immunomodulatory drug (lenalidomide) and a proteasome inhibitor. The study met its primary endpoint of improving progression-free survival (PFS).¹

This multicenter trial randomized 304 patients to receive either a subcutaneous formulation of daratumumab plus Pd versus Pd alone. The APOLLO trial was designed to confirm the results from the phase I EQUULEUS (MMY1001) study, that assessed intravenous daratumumab plus Pd in the same setting, which led to a U.S. Food and Drug Administration (FDA) approval of the combination.

Overall, the triplet combination of subcutaneous daratumumab plus Pd was consistent with the safety profiles of each individual therapy alone.